BioLife Solutions Q2 revenue rises 21% year over year

BioLife Solutions

06/08/2026 21:16

Overview
US cell processing tools maker's Q2 revenue rose 21% yr/yr to $28.5 mln
Q2 adjusted gross margin was 65%, down from 66% a year ago
Repligen to acquire BioLife in $1.5 bln deal expected to close in Q4 2026

Outlook
BioLife expects acquisition by Repligen to close in Q4 2026

Result Drivers
BIOPRESERVATION MEDIA - Co attributed Q2 revenue growth to strong performance of its biopreservation media franchise, per CEO Roderick de Greef
CLINICAL TRIAL ADOPTION - Biopreservation media used in about 250 ongoing US clinical trials, representing over 70% market share, including more than 30 Phase III trials
COMMERCIAL THERAPY EMBEDDEDNESS - Biopreservation media embedded in 18 unique commercial CGTs as of June 30, with expectations for further product approvals and geographic expansion

Company press release: ID:nPn4yKB47a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue 
 
$28.5 mln
 
Q2 Adjusted Gross Margin
 
65.00%
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for BioLife Solutions, Inc. is $31.00, about 8.3% below its August 5 closing price of $33.80
The stock recently traded at 129 times the next 12-month earnings vs. a P/E of 86 three months ago

Reuters Recommended Reads
Aug 5 - Alpha Teknova Q2 revenue beats estimates, raises revenue 2026 outlook
Aug 5 - Standard BioTools Q2 revenue falls on consumables weakness
Aug 5 - Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)